Atovaquone
규격
689-795-9EC 번호
3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dioneIUPAC 명칭
C22H19ClO3화학식
366.8 g/mol분자량
3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione; DTXSID20916694; 3-(4-(4-chlorophenyl)cyclohexyl)-4-hydroxynaphthalene-1,2-dione; RefChem:1066764; DTXCID20888847; 630-425-2; ATOVAQUONE; 95233-18-4; Mepron; Wellvone; Acuvel; cis-Atovaquone; 137732-39-9; 566C80; 94015-53-9; Atavaquone; Mepron (antipneumocystic); CIS-ATOVAQUONE (RACEMIC); Atovaquone EP Impurity B; 2-(TRANS-4-(4-CHLOROPHENYL)CYCLOHEXYL)-3-HYDROXY-1,4-NAPHTHALENEDIONE; BW 566C; 566C; C22H19ClO3; atovacuona; Atovaquona; 2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; ATOVAQUONE-D4; DTXSID7022629; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 2-((1r,4r)-4-(4-chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione; ATOVAQUONE [MI]; SpecPlus_000686; ATOVAQUONE [USAN]; MFCD00889188; F1W7QUV0KI; NSC-759582; 2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione; 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-dihydronaphthalene-1,4-dione; Y883P1Z2LT; 2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-[trans-4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione; trans-2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione; NCGC00016961-01; 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxy-naphthalene-1,2-dione; CAS-95233-18-4; 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione; 1,4-Naphthalenedione, 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-, trans-; DTXCID602629; 2-(cis-4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthalenedione; 2-(cis-4-(4-Chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione; 2-[trans-4-(p-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; cis-2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 1,4-Naphthalenedione, 2-(cis-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-; 2-((1s,4s)-4-(4-chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione; DRG-0084; BW 566C-80; Mepron (TN); BW-A 566C; HSDB 7083; BW-566C; SR-05000001438; BW-566C-80; CRL-8131 & Atovaquone; UNII-Y883P1Z2LT; 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; Atovaquone & Interleukin 12; 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-naphthalene-1,4-dione; Cis-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; Atovaquone CRS; 2-[(1r,4r)-4-(4-Chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione; Mepron;; trans-2-(4-(4-chlorophenyl) cyclohexyl)-3-hydroxynaphthalene-1,4-dione; ATO & IL-12; Atovaquone; 2-[trans-4-(4-Chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione; 566C80; Atovaquone [USAN:USP:INN:BAN]; cis-2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione; USP Atovaquone Related Compound A; Atorvastatin EP Impurity B; BW 566C80; Atovaquone (Standard); Spectrum_001743; starbld0018905; Atovaquone (Atavaquone); ATOVAQUONE [INN]; ATOVAQUONE [JAN]; Prestwick0_000534; Prestwick1_000534; Prestwick2_000534; Prestwick3_000534; Spectrum2_001665; Spectrum3_000991; Spectrum4_001117; Spectrum5_001382; UNII-F1W7QUV0KI; Atovaquone (Atavaquone)?; ATOVAQUONE [HSDB]; ATOVAQUONE [VANDF]; trans-2-(4-(4-chl; ATOVAQUONE [MART.]; ATOVAQUONE [USP-RS]; ATOVAQUONE [WHO-DD]; SCHEMBL21694; SCHEMBL21695; Atovaquone (JAN/USP/INN); BSPBio_000547; BSPBio_002681; KBioGR_001594; KBioSS_002223; MLS002153863; BIDD:GT0849; DivK1c_006782; SCHEMBL637069; SPECTRUM1504210; SPBio_001849; SPBio_002468; Atovaquone - Bio-X trade mark; BPBio1_000603; CHEMBL471792; CHEMBL519462; GTPL9695; orb1223533; orb1308475; SCHEMBL1542719; SCHEMBL1649508; SCHEMBL9975142; ATOVAQUONE [ORANGE BOOK]; Atovaquone, >=98% (HPLC); SCHEMBL29559044; CHEBI:95346; KBio1_001726; KBio2_002223; KBio2_004791; KBio2_007359; KBio3_001901; ATOVAQUONE [EP MONOGRAPH]; CHEBI:575568; KUCQYCKVKVOKAY-OTVXOJSOSA-N; ATOVAQUONE [USP MONOGRAPH]; BDBM192009; GLXC-02590; HMS1569L09; HMS1922F19; HMS2089M14; HMS2093C10; HMS2096L09; HMS2235N08; HMS3369N09; HMS3651N20; HMS3713L09; HMS5081E14; Pharmakon1600-01504210; Atovaquone EP Impurity B (RC A); MALARONE COMPONENT ATOVAQUONE; MFA73239; VHD01514; Tox21_110714; CCG-39090; EBC-06068; EBC-67042; FD7252; HY-13832R; NSC759582; s3079; STK636160; trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; Atovaquone for system suitability CRS; 1,4-Naphthalenedione, 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-; AKOS005567953; AKOS015895691; AKOS015961933; Tox21_110714_1; BW-556C-80; CCG-220534; DB01117; FA18025; NSC 759582; 2-hydroxy-3-[(1r,4r)-4-(4-chlorophenyl)cyclohexyl]-1,4-dihydronaphthalene-1,4-dione; Atovaquone 100 |Ig/mL in Acetonitrile; NCGC00016961-02; NCGC00016961-03; NCGC00016961-04; NCGC00016961-06; NCGC00016961-07; NCGC00016961-11; NCGC00095113-01; NCGC00095113-02; AC-30251; AS-12809; Atovaquone 100 microg/mL in Acetonitrile; BA164228; HY-13832; SMR001233220; SY053121; SBI-0052893.P002; A2545; AB00513855; NS00010018; NS00077594; SW219222-1; MALARONE PEDIATRIC COMPONENT ATOVAQUONE; C06835; D00236; EN300-120639; EN300-731648; F18448; SBI-0052893.0001; AB00053222-03; AB00053222_04; AB00053222_05; F390345; Q418179; SR-05000001438-1; SR-05000001438-2; SR-05000001438-4; SR-05000001438-5; Z2588038997; 2-[4-(4-chlorophenyl)cyclohexy]-3-hydroxy-1,4-naphthoquinone; 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-napthoquinone; 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1.4-naphthoquinone; 3-[4-(p-chlorophenyl)cyclohexyl]-4-hydroxy-1,2-naphthoquinone; 1,2-Naphthalenedione, 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxy-; 1,4-Naphthalenedione, 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-; 2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxynaphthoquinone, trans-; cis -2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione; cis-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; Atovaquone Related Compound A (USP); Atovaquone Imp. B (EP); 296C85; USP Atovaquone Related Compound A; GR 261266X동의어
Atovaquone 함유 제품
말라론정WELLVONE 750 mg/5 ml, suspension buvableMALARONE 62,5 mg/25 mg ENFANTS, comprimé pelliculéMALARONE 250 mg/100 mg, comprimé pelliculéATOVAQUONE/PROGUANIL ZENTIVA 62,5 mg/25 mg ENFANTS, comprimé pelliculéATOVAQUONE/PROGUANIL ZENTIVA 250 mg/100 mg, comprimé pelliculéATOVAQUONE/PROGUANIL VIATRIS 250 mg/100 mg, comprimé pelliculéATOVAQUONE/PROGUANIL TEVA 62,5 mg/25 mg ENFANTS, comprimé pelliculéATOVAQUONE/PROGUANIL TEVA 250 mg/100 mg, comprimé pelliculéATOVAQUONE/PROGUANIL EG 250 mg/100 mg, comprimé pelliculéATOVAQUONE/PROGUANIL BIOGARAN 62,5 mg/25 mg ENFANTS, comprimé pelliculéATOVAQUONE/PROGUANIL BIOGARAN 250 mg/100 mg, comprimé pelliculé
1/2 페이지
